Skip to main content
. 2017 Dec 22;3(2):e000567. doi: 10.1136/rmdopen-2017-000567

Table 2.

Structural disease progression at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARD or MTX

Concomitant
treatment		 cDMARD MTX None
(cDMARD-naïve or past use at baseline)
PBO, n=58 IXEQ4W, n=63 IXEQ2W, n=60 PBO, n=48 IXEQ4W, n=52 IXEQ2W, n=49 PBO,
n=35		 IXEQ4W, n=37 IXEQ2W, n=37
mTSS LSM change from baseline at week 24 (SE) 0.44
(0.100)		 0.11
(0.096)*		 0.11
(0.098)*		 0.52
(0.135)		 0.13
(0.121)*		 0.14
(0.114)*		 0.57
(0.157)		 0.25
(0.153)		 0.03
(0.153)*

The study was not designed to test equivalence or non-inferiority of treatment with ixekizumab alone versus treatment with ixekizumab with concomitant cDMARDs.

*P<0.05 versus PBO.

cDMARD, conventional disease-modifying antirheumatic drugs; IXEQ2W, 80 mg ixekizumab once every 2 weeks; IXEQ4W, 80 mg ixekizumab once every 4 weeks; LSM, least squares mean; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; n, number of patients; PBO, placebo.